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Abstract: The papillomavirus family is known to be responsible for a quarter of virus-related cancers worldwide. High-
risk types are the causative agents of anogenital, cervical and various cancers of the mouth, throat, intestines,
vagina, penis and anus. Cervical cancer and various other malignancies induced by papillomaviruses are a
global health problem, and the growing prevalence of these diseases indicates the need to increase awareness
of this viral family. In this review, published articles during 2001-2020 were searched using keywords such as
Papillomavirus, Cervical Cancer and Papilloma Vaccine. Our review represents the results of the association
of high-risk HPV serotypes with many malignancies in human. Furthermore, issues such as HPV vaccination,
cervical cancer screening, and other preventive programs worldwide are discussed.
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1. Introduction
Papilloma viruses are small circular double-stranded DNA
viruses. According to the latest International Committee on
Taxonomy of Viruses classification in 2019, papilloma viruses
are in the realm of Monodnaviria, Shotokuvirae kingdom,
Cossaviricota phylum, Papovaviricetes class, Zurhausenvi-
rals genus, Papillomaviridae family with two first and sec-
ond papilomavirinae subfamilies with 53 genera and 133
species. Human papilloma virus (HPV) is divided into five
groups: alpha, beta, gamma, mupa, and juvenile. Most
alpha-papillomaviruses infect mucosal surfaces in the gen-
ital and non-genital organs and are also called "mucosal-
genital". These viruses have a strong tendency to infect basal
keratinocyte cells on the surface of the skin and mucous
membranes (1).
Until the 19th century, genital warts were known as syphilis
or gonorrhea. The viral nature of these warts became known
in the early 1990s after examining cells isolated from these
lesions. The nature of the animal papilloma virus was also
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identified in 1930 by Richard Shop (2). Historically, papil-
loma viruses, along with polyoma viruses, were known as
papova viruses, but after examining the genomic sequence
and replication mechanisms, each was finally introduced as
an independent family in 2000. To date, more than 200 pa-
pilloma virus genotypes have been identified, only a limited
number of which are associated with cancer, and based on
this association, they are divided into high-risk and low-risk
types (3). Clinical manifestations in low-risk types may range
from completely asymptomatic to changes in the form of pa-
pillomas and benign warts. In contrast, high-risk types of
HPV have been identified as causative agents of anogenital,
cervical, and various cancers of the mouth, throat, intestines,
vagina, penis, and anus (4, 5).
According to the latest classification of the International Cen-
ter for Cancer Studies (IARC), 20 types of papilloma viruses
fall into group one, which includes high-risk or carcinogenic
infectious agents for humans. These 20 types include types
16, 18, 31, 33, 34, 35, 39, 42, 44,45, 51, 52, 56, 58, 59, 66, 68,
70, 73 and 82. Types 16 and 18 are more common and are re-
sponsible for about 70% of cervical cancers worldwide, and
type 16 alone is responsible for about 60% of oropharyngeal
cancers worldwide. Stability of high-risk types is a key step
in the transformation of natural epithelium into precancer-
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ous and cancerous lesions (6-9). Due to the growing trend of
this disease in different age and sex groups and the develop-
ment of various programs in the prevention and treatment of
diseases this study was conducted in developed and devel-
oping countries to raise awareness about papilloma viruses
and their association with human diseases.
This review aimed to raise awareness of papilloma viruses
and their relationship with human diseases and cancers by
searching the databases of Google Scholar, ISI, PubMed,
Google search engine and a comprehensive review of pub-
lished articles in this field in order to review articles related
to this study were used to search for papillomavirus, cer-
vical cancer and papilloma vaccine to raise awareness of
papilloma viruses and their risks for humans and preven-
tion methods. We included articles that matched the search
terms. Articles that were less relevant to the topic or provided
incomplete data were excluded from the study. Ultimately, 80
articles were used.
1.1. Genome structure and function of papillo-
mavirus proteins
Papilloma viruses are 60 nanometers in diameter and have
a genome of about 8,000 bp. These viruses are uncoated
and have an icosahedral capsid. The genome of papilloma
viruses consists of three functional regions: Early region E
(functional region), the secondary genes region or L region
(Late region), the controlling region, and the coding LCR re-
gion or UR (upper regulation) region. The early region in-
cludes E6, E5, E4, E2, E1 and E7, which are involved in viral
replication and carcinogenicity. The late region encodes the
structural proteins L1 and L2 for the viral capsid. The reg-
ulatory region or Long control region includes the original
primary promoter called p97 and the DNA replication regula-
tory sequences. Table 1 shows the proteins and their function
in human papilloma viruses.
1.2. Papilloma virus replication cycle
The life cycle of this virus depends on the differentiation of
epithelial cells. Because papilloma viruses do not encode
DNA polymerase and other required factors themselves, their
replication is highly dependent on the host cell. Binding
of the virus with L1 to its specific receptors, heparan sul-
fate proteoglycans (HSPGs) and a number of secondary cel-
lular receptors, including integrins, tetraspanins, growth fac-
tor receptors, and anxin A2, causes the virus to enter the cell.
HSPGs alter the structure of L2 Cyclophylline B, a cell surface
chaperone in the luminal membrane, helps establish a cut-
off site for furin convertase at the N-terminal L2 by cleaving
this region and separating 12 amino acids from the end of
the L1 protein. It can bind to its secondary receptors and be
transmitted to the endosome through endocytosis.
Low pH in the endosome space leads to the opening of the
capsid and the virus enters the cell by the mechanism of en-
docytosis through clathrin. The virus genome enters the nu-
cleus and remains as a small circular chromosome in the nu-
cleus. Many chronic viruses retain their DNA by integrat-
ing into the host genome, but HPVs retain their genome as
extrachromosomal episomes that attach to the host DNA.
The primary genes of the virus are transcribed, leading to
the amplification phase and the proliferation of 50 to 400
copies of DNA per cell. This phase of genome amplification
is called "plasmid proliferation". After that, the viral genome
multiplies almost once with each cell division, and the viral
genome divides evenly among the daughter cells.
To ensure that the viral genome is not lost during cell divi-
sion, there is a binding mechanism between viral DNA and
host mitotic chromosomes that is mediated through some
cellular mediators and viral proteins such as E2. When stem
cells differentiate into stable keratinocytes, we see an explo-
sion of viral DNA replication, known as the "vegetative prolif-
eration" phase, which eventually leads to a production phase
with the production of thousands of viral copies in the in-
fected cell. This is followed by late gene expression and virus
assembly. The viral particles then accumulate in the nucleus
and are released on the surface of the lesion after cell death.
The presence of cellular factors is essential for viral replica-
tion (11-13). Figure 1 shows papilloma virus infection of the
cervix with organized expression of viral proteins following
keratinocyte differentiation (14).
2. Methods
International databases such as PubMed, Web of Sciences,
and Scopus were searched using various keywords such as
Human Papilloma Virus, Cervical cancer, HPV, and Papilloma
Virus within January 2001 until December 2020. Inclusion
criteria was defined as any study investigating the relation-
ship of HPV with human cancers, those assessing vaccine
effectiveness or efficacy, and those related to the dormant
course of HPV infection. Amongst which, articles assessing
non-human hosts, and those investigating other serotypes of
HPV other than high-risk ones were excluded. Screening of
the extracted articles were performed by two independent vi-
rologist experts with a medical background.
3. Results
3.1. The natural course of infection with the pa-
pilloma virus
Most HPV infections are transient and asymptomatic and
do not cause clinical problems, so most sexually active peo-
ple may develop and recover from an HPV infection without
ever realizing it. The virus does not have the effect of ping
pong, meaning that a couple in a relationship does not in-
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fect each other frequently. After a person comes in contact
with a genotype of HPV and clears it, the person is likely to
become immune to that particular genotype, so re-infection
can occur with a new type of HPV in a new contact. The aver-
age infection time with a new genotype is approximately 9.8
months in men and women.
Common viral types in the genitals can be found in asexual
areas such as hands, nails and underwear, but the presence
of the virus in these areas is an efficient mode of transmis-
sion of the virus has not yet been proven (15, 16). Low-risk
types 6 and 11 are responsible for benign lesions that occur
in the head, neck, and face. These lesions may spread to the
lips, lungs, trachea, nose, and oral cavity, hoarse voice and
rare diseases of oral epithelial hyperplasia (Heck). Epider-
modysplasia verruciformis is a chronic genetic skin infection
associated with the EVER1 and EVER2 genes that causes flat
warts. Papilloma virus types 5, 8, 9, 12, 14, 15, 17, 19, 25, 36,
38, 47 and 50 along with genetic mutations are the causes of
this disease (17, 18).
3.2. Pathogenicity of papilloma viruses
The papilloma virus family is responsible for a quarter of all
cancers associated with the virus and about 4.5% (640,000
cases) of cancer worldwide (19). One of the hypotheses re-
garding the pathogenicity of papilloma virus is related to its
integration into the human genome. Studies show that inte-
gration with the human genome, in addition to possibly be-
ing associated with virus stability in the body, can also play
a role in the process of viral DNA methylation. Study on
HPV16 in the human genome fusion mode shows that the
viral genome in this state can be affected by methylation in
human genes adjacent to the fusion point and activate or in-
activate some of its genes by the spontaneous methylation
mechanism. For example, methylation in the L1 gene se-
quence can act against the host defense mechanism and play
a role in the development of infection. On the other hand,
methylation in the region related to E2 gene suppresses E2
expression and thus reduces the expression of E6/E7 onco-
genes (20, 21).
3.3. Pathogenicity in men
According to the statistics, genital infections with papillo-
mavirus are more common in men than women, but these
infections rarely persist. Few studies have been performed
on papilloma virus infection in men anatomically, however,
infection is most common in the penis and least common in
the urethra. Especially in men it is increasing rapidly. More
than 70% of the approximately 12,000 cases of oropharyn-
geal cancer diagnosed each year are due to HPV, and approx-
imately 90% of HPV-positive cases are due to HPV16 and the
rest are due to other types of papilloma. The prevalence of
these cancers is higher in men than in women (22). Regard-
ing anal infections, most studies have been performed on
HIV-positive as well as gay men. These studies have shown
a high prevalence of HPV infection. Overall, HPV anal in-
fections have been reported in 58.8% of gay men, 30.7% of
women, and 14.2% of heterosexual men (8). Oral HPV infec-
tions are less common and more common in men. The statis-
tics in this regard are very variable because the reports are in-
fluenced by sampling methods and the population studied. A
study in the United States reported an average prevalence of
10.1% in men and 3.6% in women (23).
3.4. Genital warts
Genital warts are a common in papilloma virus infections, es-
pecially low-risk genotypes 11 and 6. These two types are re-
sponsible for about 90% of genital warts. Although epidermal
manifestations such as warts or candidiasis occur in only 1%
of cases of low-risk types, in the case of lesions, the average
time of infection and genital warts in men is 11-12 months
and in women 5-6 months (24).
3.5. Papilloma virus and carcinogenic mecha-
nisms
Cancer is the result of abnormal cell proliferation. In can-
cer cells, a variety of mutagens, oncogenic viruses, and repli-
cation errors, genetic alterations, and alterations in DNA
methylation may disrupt cell cycle regulation, as well as ef-
fect on proto-oncogenes and tumor suppressors genes (25).
Environment including UV and X-rays, chemical agents such
as mutagens and carcinogens, and infectious agents such as
bacteria and viruses can lead to the development of cancer.
High-risk papilloma viruses, such as HPV 16 and 18 are as-
sociated with human cancer because they encode the two
transforming proteins E6 and E7 (26, 27). After breast can-
cer, the prevalence and morbidity and mortality of cervical
cancer has the second place in developing countries and is
the third leading cause of cancer death among women (28).
Intraepithelial neoplasia of the cervix (CIN), which is a pri-
mary event in cervical cancer, is classified into three cate-
gories in terms of histological severity: CIN I, CIN II, CIN III
(29). Genes cause cell deformation and cancer. HPV E7 pro-
tein can bind to the retinoblastoma suppressor tumor (RB,
a member of the P130 protein family (RBL2) and increase its
protease-mediated degradation (30). In addition, HPV E7 can
bind to the MuvB nucleus complex associated with BMYB
and FOXM1 and activate gene expression in the G2 and M
phases of the cell cycle. Thus, HPV-16 E7 acts by inhibiting
cell cycle exit and increases mitotic proliferation (31). In-
duced cervical cancers in transgenic mice expressing HPV-
16 E7 require continuous expression of E7 to preserve the tu-
mor, even in the presence of E6, persistent expression of E7 is
required for survival of cervical cancers and most precancer-
ous lesions (32). Protein E6, along with protein E7, stabilizes
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epithelial cells and increases the expression of human TERT
(reverse telomere transcriptase) protein (33). The main ac-
tivity of E6 protein, is the destruction of p53 protein through
ubiquitination. The binding of E6 to p53 and its ubiquitina-
tion to E6- (AP) is dependent on cellular E6 protein. P53 is
a transcription factor that stimulates the expression of genes
involved in cell cycle arrest and apoptosis, such as p21. In-
hibition of translocation and degradation by p53 by E6 pre-
vents the activation or suppression of gene transcription by
P53. E6 can also increase the regulation of cell telomerase
complex activity. This enzyme stores telomeric DNA at the
ends of chromosomes, and the lack of telomerase enzyme
causes the telomeres to gradually shorten with each cell di-
vision. Telomere shortening controls the number of cell divi-
sions (34). Overall, HPV is responsible for about 96% of cervi-
cal cancers, 93% of anal cancers, 64% of vaginal cancers, 51%
of vulvar cancers, 36% of penile cancers, and 63% of oropha-
ryngeal cancers (35).
3.6. Cervical cancer
Cervical cancer is found among many women around the
world. More than 90% of cervical cancers are caused by high-
risk HPV genotypes and 70% are genotypes 16 and 18 (36-
38). Cervical cancer is one of the most common cancers in
women worldwide and one of the leading causes of cancer
death in developing countries (39). The cervix is the area be-
low the uterus that connects the uterus to the vagina. The
cervix has two parts and is covered with two types of cells.
The part near the uterus or endocervix is covered with glan-
dular cells. The part that is closest to the vagina, called the
exocervix, is covered with squamous cells. These two types
of cells are connected in an area called the conversion area.
Most cervical cancers occur in this area. Normal cells first
transform into precancerous lesions. Several terms are used
in connection with precancerous lesions in this area: cervi-
cal intraepithelial neoplasia (CIN), squamous intraepithelial
lesion (SIL), and dysplasia. It usually takes several years for
cancerous lesions to turn into cancer. According to studies,
HPV was diagnosed in about 74.8% of low-grade cervical le-
sions (including LSIL and CIN1) and 88.9% of high-grade cer-
vical lesions (including HSIL and CIN2 / CIN3). The likeli-
hood of the virus increasing with the severity of the lesions
increases. Among these, HPV16 genotype has been identified
in 3.19% of low-grade lesions and 1.45% of high-grade lesions
(25) (figure 2).
3.7. Risk factors for cervical cancer
Having high-risk types of HPV, early onset of sexual activ-
ity (less than 16 years old) since the T-zone in the cervix
has not yet reached full maturity and is more vulnerable
to HPV infection, a large number of sexual partners (more
than 4), receiving immunosuppressive therapies (such as
corticosteroids), malnutrition and strictly restricted diets,
prolonged smoking, oral contraceptives, high birth rates,
multiple births, chronic vaginal inflammation to other sex-
ually transmitted diseases (Chlamydia, Mycoplasma, HSV,
Haemophilus ducreyi, Trichomonas vaginalis, etc.) are im-
portant risk factors for cervical cancer. However, not per-
forming routine screening for cervical cancer is still the most
important risk factor (8, 11, 40). Asexual routes of transmis-
sion, such as transmission from mother to fetus through the
birth canal or medical devices (such as vaginal ultrasound
probes) are less common (8, 40).
3.8. Screening for HPV infection
Since more than 90% of HPV infections go away on their own
within two years, screening for Pap smears every three years
is enough between the ages of 21 and 29, and there is no need
for co-testing (HPV and Pap smear). In the age range of 30 to
65 years, it is recommended that co-testing be performed ev-
ery five years. For women over 65 years of age: If they do not
have a previous history of cervical cancer or CIN2 / 3, they
may have adequate negative screening status (referred to as
those who have had three consecutive normal Pap smears or
two tests in the last 10 years). Normal Pap smear with a con-
comitant negative HPV test and at least one of these tests in
the last 5 years indicates that screening in these women can
be discontinued.
If any of the above (history of cervical cancer, CIN2/3, etc.)
are present, screening should be continued for another 20
years. In patients with a history of CIN2/3 in the last 20 years,
individuals with HIV, people with suppressed immune sys-
tems (such as transplant recipients) need to be screened for
HPV annually. Screening can be stopped if a person has had a
hysterectomy (removal of the uterus) with cervical resection
and has no history of cervical cancer or CIN2/3, but if the per-
son has a history of CIN2/3 and even if the cervix is removed
or even over 65 years old, HPV screening in the vaginal cuff
should continue for up to 20 years. HPV screening should
also be continued if the hysterectomy is performed without
removing the cervix.
3.9. New screening protocol
As of April 24, 2014, the FDA has approved the use of the
Cobas HPV test alone as a preliminary screening test in
women 25 years of age and older that identified the types 16
and 18 separately. In addition, BD On clarity HPV Assay, also
known as the Aptima method in Iran, has been accepted by
the FDA as the primary screening test in women, which de-
termines 14 high-risk types of HPV undifferentiated, and the
16, 18, 45 types separately (41).
Screening with First line HPV testing or High Risk HPV test-
ing begins at age 25 and stops at age 74, and screening in-
tervals change every 5 years. Studies show that this method
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can provide more protection against CIN3 and cervical can-
cer than cytology (42). At the same time, in addition to sam-
pling and performing diagnostic tests for the virus, the man-
agement of positive cases of the disease should be practiced
in the screening program, (figure 3) (43)
3.10. Prevention of sexual transmission of papil-
loma virus
Although avoiding unprotected sex is the safest way to pre-
vent infection with the virus, it can be done in other situa-
tions, including monogamy and limiting the number of sex-
ual partners, condom use, removal of genital warts, and HPV
vaccination. However, it should be borne in mind that HPV
infection is so common that most infected people infect their
sexual partner before seeing a doctor, so even in people with
a sexual partner for life it is also possible to be infected. Al-
though the use of an IUD with a 50% reduction in cervical
cancer has played a protective role, the potential protective
mechanisms of the IUD remain unknown. Located in the
cervix, it creates a protective inflammation or leads to the
mechanical elimination of HPV-related damage (44).
3.11. Diagnosis of papillomavirus infection
Unlike many viruses, papilloma viruses cannot be cultured in
monolayer cell cultures. The history and prevalence of HPV
in the cervix are well described. Recognition of the various di-
mensions of precancerous and cancerous lesions in this area,
along with diagnostic tests including the search for viral DNA
in the lesions as well as the search for HPV-specific antibod-
ies, are known as biological markers in papillomavirus patho-
genesis (23, (45)). Pap smear is used to check for different
types of cervical lesions. In this test, cervical cells are col-
lected with a swab and examined after Pap smear. Southern
Blot, In Situ Hybridization, and Dot Blot Hybridization tests
are hybridization-based diagnostic methods (46, 47). How-
ever, molecular detection is necessary to accurately identify
the type of HPV to determine the risk and isolate low-risk and
high-risk types. These methods include PCR, PCR-RFLP, Real
Time PCR, and microarray (35, 48).
there is currently no approved test for HPV in men. Rou-
tine testing (also called ’screening’) to check for HPV or HPV-
related disease before there are signs or symptom, is not rec-
ommended by the CDC for anal, penile, or throat cancers in
men in the United States. However, some doctors perform
anal tests Pap smears are used for gay and bisexual men who
are at high risk for HPV-induced anal cancer. Studies also
use HPV testing to detect the virus in men, making cell dam-
age impossible. Oral human papillomavirus is found in men
through Oral rinse/gargle specimens. For HPV DNA test-
ing, samples are taken from the, coronal sulcus, glans penis,
shaft, and scrotum (49).
3.12. Vaccination
Three commercial papilloma virus vaccines are licensed for
use by both the FDA and EMA for men and women. These
vaccines are used in women aged 13 to 26 years and men
from 13 to 21 years. According to the ACIP recommenda-
tion, HPV vaccination can be started from the age of 9 (50).
Gardasil (qHPVv) which contains four types of HPV 6, 11, 16,
18was approved for use in 2006. Gardasil 9, in addition to the
four mentioned types, also includes 5 types of HPV 31, 33,
45, 52 ,58 (51). The cervarix vaccine (bHPVv) was approved
in 2007 and covers two high-risk types of HPV16,18. All three
vaccines contain non-infectious and inactivated subunits of
the virus. The difference between these vaccines is in the ad-
juvant compounds used in them. In Gardelsil vaccine, alu-
minum hydroxyphosphate sulfate is used as an adjuvant and
in Cervarix, one of the compounds of lipid A and aluminum
is used as an adjuvant. These vaccines also differ in the man-
ufacturer’s expression system. Recombinant proteins in Gar-
dasil are produced by Saccharomyces cerevisiae cells and in
the cervix by Trichoplasia cells infected with the L1 gene bac-
ulovirus.
Both vaccines have been successful in preventing HPV16,18-
associated precancerous lesions in women with no previous
history of papilloma virus infection in clinical trials of level
3 to about 90%. qHPVv also protects against types 6 and 11
and all types of genital warts. In a study of more than 4,000
men, it was found that vaccination in men and boys with qH-
PVv could reduce the incidence of genital warts. All three
vaccines contain L1 proteins specific for the HPVs in ques-
tion, produced by recombinant technologies, known as non-
infectious viral-like particles, or VLPs. As long as VLPs lack
viral DNA, they cannot infect, proliferate, or cause disease.
According to studies to date, the average serum level of anti-
bodies protecting against types 16 and 18 is up to 100% de-
tectable with serum ELISA. However, universal access to and
use of vaccines may not be available to all, especially in de-
veloping countries where disease is more prevalent ((1), (52,
53)). Studies on the long-term protective effects and side ef-
fects of vaccines require studies and follow-up. It is in a long
period of time and otherwise it is not predictable (54).
According to the ACOG Committee’s latest theory on the
HPV vaccine in August 2020, the vaccine should be given to
women 27 to 45 years of age based on clinical decisions based
on obstetricians and other health care providers, in the case
of a former patient. Use of medical experience. This prescrip-
tion approval, in the above age group, is only for the 9-valent
vaccine and does not include the quadrivalent and divalent
vaccines. These vaccines have no therapeutic properties, and
if a woman is vaccinated before starting sexual activity or ex-
posure to HPV, the vaccine will be more effective. However,
if you are already infected with one type of HPV, getting vac-
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cinated against that type of virus will not provide immunity,
but it will provide immunity against other types of HPV that
are present in the vaccine and in general, patients with any
current HPV lesion that is in the high-risk group as carriers of
HPV, vaccination can reduce the risk of transmitting the virus
from one person to another (50, 55).
4. Discussion
Cervical cancer is the second most common preventable
cancer among women worldwide (56). According to the
IARC, about 530,000 new cases of cervical cancer are reported
worldwide each year, and more than 288,000 women world-
wide die as a result. More than 80% of these cases have been
reported in developing countries. Papilloma virus types 16
and 18 together account for about 70% of cervical cancers
worldwide, and type 16 alone is responsible for about 60%
of Oropharyngeal cancers. Stability of high-risk types is a key
step in the transformation of normal epithelium into precan-
cerous and cancerous lesions (8, 56, 57).
About 9,300 men in the United States are diagnosed with
HPV-induced cancers each year, including those with oral-
pharyngeal cancers, although studies have shown that Gar-
dasil vaccine is cost-effective for men and prevents throat
and throat cancers. In women, the Gardasil and Cervarix vac-
cines also protect against 70% of cervical cancers and 90% of
genital warts (58). These vaccines are typically more effective
in the 15-19 year age group than in the 19-25 year age group.
The vaccine is probably less effective at older ages due to the
presence of refractory infections at the time of vaccination in
these women (59). According to several articles, there is no
specific treatment for HPV infection. Eliminating treatments
such as cryotherapy, trichloroacetic acid, laser and surgical
resection are used to treat precancerous lesions (60, 61). A
study on the antitumor effect of HPV-DNA therapeutic vac-
cines with a chitosan-based nanoparticle gene delivery sys-
tem to efficiently deliver the DNA-HPV16 E7 vaccine to im-
prove immunization-induced immunization in mice showed
that mice vaccinated with chitosan carriers were able to pro-
duce strong anticoagulant and protective effects with strong
stimulation of TCD8 + and interferon gamma against tu-
mors caused by E7HPV protein, and with this method, they
took a step towards cervical cancer immunotherapy. Thera-
peutic effect of chitosan-based nanotechnology suggests that
nanoparticles may be an effective carrier for improving the
immunization of DNA vaccination and that this substrate
could be used as a potential candidate for cancer vaccination
in humans (40).
Cervical cancer and many other HPV-induced malignancies
are very common. In 2015, Grabuska and colleagues consid-
ered new therapies as a viable option for the treatment of
HPV infections and precancerous lesions, as well as for the
treatment of HPV diseases (62). Vaccines are one of the most
prominent achievements in the history of medicine, which
play an effective role in increasing the quality of human life
by reducing or eliminating the complications of infectious
diseases. About three million children and nearly six million
people will be saved each year by vaccines. In addition, vac-
cines are essential medical tools to fight cancer, side effects
of viral and bacterial infections such as HPV, HIV, meningitis,
autoimmune diseases, and more. However, there are still im-
portant pathogens for which no vaccine has been developed
and vaccines that still need to be upgraded (63).
Studies show that more than 63 million women and girls
worldwide are vaccinated with Gardasil vaccine and more
than 19 million with Cervarix vaccine. However, problems
such as lack of knowledge, high cost of vaccine production
and distribution, difficulties in producing and purifying re-
combinant proteins in eukaryotic systems, and the need for
cold chain storage and transmission of vaccines, vaccination
complications, are barriers to public use of this vaccine. Is
(1, 52, 53), (64-66). There is currently no strategy to mod-
ify the structure of VLPs in existing L1 protein vaccines, but
many studies are underway to reduce production costs and
use low-cost expression systems such as bacteria (1). In 2015,
the Gardasil 9 vaccine was shown to increase the efficacy of
the quaternary Gardasil vaccine from 70% to 90% in cervi-
cal cancer. It is approximately 90% effective in HPV-related
vulvar, vaginal, and anal cancers (51). The CDC has not men-
tioned any serious side effects from HPV vaccination, and in
general, the benefits of using the vaccine outweigh its poten-
tial risks, and in this regard, of course, to reduce side effects
such as dizziness and hypotension, etc. it is recommended
that the vaccine be injected while lying down or sitting and
stays in the same position for 15 minutes after injection (67).
A comprehensive study was launched by the International
Agency for Research on Cancer and the University of Oxford
on 16,573 women with cervical cancer and 35,509 women
without cervical cancer from 26 countries worldwide, and
almost half of the studies were in less developed countries.
Cervical cancer was studied and their role was examined by
considering the age of individuals and the effect of behavioral
factors on cervical cancer risk such as smoking, use of oral
contraceptives, and high number of deliveries (more than 5
complete deliveries). All factors independently doubled the
risk of cervical cancer, while continuous smoking increased
the risk by 46%, and a large body of prospective European re-
search on cancer and nutrition found that doubling CIN3 in
cervical cancer is associated with the duration and frequency
of smoking (68-72). According to a study in 2019, using the
results of a clinical trial of a 9-valent vaccine against papil-
loma virus in women aged 26 to 45 years, the Food and Drug
Administration raised the approved age for use of this vac-
cine from 9-26 years to 9-45 years (73).
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5. Conclusion
According to international statistics, cervical cancer is one of
the most common cancers in women in the world with an
annual infection of about 530,000 women, and with the sta-
bilization of high-risk types of HPV, this cancer is constantly
increasing. To reduce the complications of papillomavirus
infection, appropriate preventive and therapeutic measures
such as timely vaccination, attention to new therapies, edu-
cation and correction of sexual misconduct, recognition and
correction of susceptible to these infections such as smoking
and overuse an overdose of contraceptives is essential to pre-
vent the growing trend of papillomavirus disease.
Screening can provide a clearer perspective for the control
and management of diseases caused by this virus in human
society, especially in developing countries. Therefore, in or-
der to achieve such goals, by using these tools, by establish-
ing a registration system and providing basic health informa-
tion with the ability to track and train program managers,
public education, program management and quality control
measures, we can hope to achieve approved global goals and
programs. Since 2018, the world health strategy has focused
on eradicating cervical cancer as a global health problem.
Therefore, preventing infection through vaccination, screen-
ing, and treatment of precancerous lesions, and identifying
and treating their primary invasive cancers, is a must-do. As
a result, up-to-date measures to prevent it seem vital. In this
regard, the program of proper disease registration and pro-
viding free screening methods, appropriate treatment mea-
sures and adequate training on the need to use these meth-
ods along with strategies to overcome vaccination barriers, is
of great importance. Also, recognizing the types of papilloma
virus that cause cancer and examining their prevalence can
be associated with vaccine design and creating a higher im-
mune coverage with fewer complications in the community.
Research in the field of new vaccines and therapies is one of
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Figure 1: Cervical viral infection, keratinocyte differentiation and expression of human papillomavirus proteins (14).
Figure 2: Overview of the process of cervical cancer with the stabilization of HPV. Top row cytology and bottom row is the result of colposcopy
(8).
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Figure 3: Papillomavirus-based cervical cancer screening program algorithm including main interventions, timeline and main bottlenecks
(43).
Table 1: Overview of the function of HPV proteins (10)
Protein Protein function
E1 Essential for viral replication and control of gene transcription - Helicase function - ATPase function
E2 Cell transcription factor - essential for viral replication and control of gene transcription - inhibition of transcription of E6
and E7 genes
E4 Degradation of the cytoskeleton to increase the release of the virus from the cell - role in virus assembly
E5 Binding to EGF cell growth factor and increasing cell growth and transformation in mice - oncoprotein in bovine papilloma -
reduction of MHC class 2 and inhibition of endosome acidification
E6 P53 depletion - anti - apoptotic effect - telomerase activation - cell immortality by inhibiting cellular apoptosis
E7 RB binding and inactivation - activation of E2F-dependent promoters - induction of genomic instability
L1 Capsid core protein - VIP formation
L2 Capsid sub - protein - involvement in the nuclear transport of viral DNA
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